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Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is an illicit drug of abuse that possesses in addition to its amphetamine-like stimulant effects also hallucinogenic properties, leading to feelings of energy, friendliness, euphoria and empathy [1] [2] [3] [4] . After decreasing numbers of MDMA seizures in recent years, most likely due to its non-availability on the illicit drug market, the Substance Abuse and Mental Health Services Administration and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) have reported on increasing MDMA consumption in the United States and Europe again since 2010 [5, 6] .
Consumption of MDMA may lead to severe acute poisonings including symptoms such as tachycardia, hypertension, hyperthermia, or serotonin syndrome [1, 2] . Neurotoxic effects to serotonic neurons have been described, but are still controversial discussed in terms of species and dosing [7] [8] [9] . MDMA metabolism is suspected to be responsible for neurotoxicity presumably through the formation of glutathion adducts [10] [11] [12] [13] [14] [15] [16] . HMMA can be further conjugated by UDP-glucuronyltransferases or by sulfotransferases. A minor pathway includes demethylation to 3,4-methylendioxyamphetamine (MDA) followed by demethylenation to 3,4-dihydroxyamphetamine, O-methylation to 4-hydroxy-3-methoxyamphetamine (HMA) and conjugation [17] [18] [19] . In urine samples of recreational MDMA users following a controlled single dose of MDMA, DHMA 3-sulfate, HMMA 4-sulfate and HMMA 4-glucuronide were detected as major metabolites next to unchanged MDMA [20] .
Chemically, MDMA is a ring-substituted phenylalkylamine derivative that possesses a chiral center. Different properties regarding pharmacological effects, neurotoxicity and in vivo kinetics for the two enantiomers R-and S-MDMA are described [1, 2, 21-24]. The Senantiomer is eliminated at a higher rate than the R-enantiomer [1, 2, 21-24] most likely explained by stereoselective metabolism as claimed in various vitro experiments [25] [26] [27] [28] .
In order to perform systematic pharmacokinetic studies on the stereoselectivity in vivo, respective analytical methods are needed. So far, the most commonly used instrumental technique for chiral analysis of MDMA and metabolites, is gas chromatography-mass spectrometry (GC-MS). Mainly derivatization with different chiral derivatization reagents is employed, leading to the formation of diastereomers which can be separated by achiral chromatography methods [25, [29] [30] [31] [32] . All these methods require hydrolysis procedures of glucuronides and sulfates. However, for complete investigation of stereoselectivity in MDMA metabolism monitoring the intact phase II metabolites is of major importance. Methods, especially stereoselective ones, for phase II metabolites of MDMA are scarce in the literature. analysis of MDMA as well as of HMMA sulfate and HMMA glucuronide in urine, but unfortunately this method did not cover DHMA sulfates [35] . To the best of our knowledge no stereoselective methods for detection and quantification of MDMA and all relevant phase II metabolites in blood plasma are available at the moment. Therefore, the aim of the presented study was the development and validation of a stereoselective method for simultaneous analysis of MDMA and all relevant phase I and phase II metabolites in human blood plasma. This method should be used for the analysis of blood plasma samples from a double-blind, placebo-controlled, crossover study with 125 mg of MDMA. 
Experimental Chemicals and reagents

Hydrochlorides
S-MDMA was a kind gift of The Department of Experimental and Clinical Pharmacology and
Toxicology, Saarland University, Germany and had been prepared through enantioseparation of racemic MDMA as described in ref. [25] . Water was purified with a Millipore filtration unit and acetonitrile (ACN) and methanol of HPLC grade were obtained from Fluka (Buchs, Switzerland). All other chemicals used were from Merck (Zug, Switzerland) and of the highest grade available.
LC-MS/MS Method Development
Sample preparation for method development
To 50 µL of each analyte solution (100 µM each) 100 µL of carbonate buffer (1 M, pH 9) and 100 µL of DNPV (0.3 % in acetone) were added and the mixture was left in a heating block for 30 min at 50°C. Afterwards the reaction was stopped by the addition of 20 µL 1M HCl.
Finally, 180 µL of a mixture of mobile phase A and B (1:1, v/v, see below) were added and aliquots of 10 µL of this solution were injected into the LC-MS/MS system.
Optimization of MS parameters
The analysis was performed using a Thermo Fischer Ultimate 3000 UHPLC (Thermo Fisher, San Jose, California, USA) system coupled to an ABSciex 5500 QTtrap linear ion trap (LIT) quadrupole mass spectrometer (ABSciex, Darmstadt/Germany). The Turbo V ion source was operated in positive ESI mode with the following MS conditions: gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 4500; ion-source temperature, 550 °C; curtain gas, nitrogen (30 psi), collision gas, medium. The MS was operated in the enhanced product ion (EPI) scan mode using the following settings: mass range 50-1000, scan rate 10,000 Da/s, dynamic fill time.
EPI scans were recorded for the expected protonated molecular ion of the potentially underivatized and of the one-, two-, and threefoldly derivatized analytes, respectively. Two runs were performed for each substance, first with collision energy (CE) set to 10 eV, second with a CE of 40 eV.
Chromatography optimization
Different mobile phases were tested on a Phenomenex (Aschaffenburg, Germany) Kinetex C18 column (100 x 2.1 mm, 2.6 µm) for the stereoselective separation of all analytes. First experiments were performed using gradient elution with 25 mM ammonium acetate buffer in 
Determination of elution order of R and S enantiomers
Elution order of R and S enantiomers of MDA, DHMA, HMMA, DHMA 3-sulfate, DHMA 4-sulfate and HMMA 4-sulfate were evaluated using incubations of S-MDMA with human liver S9 fraction (HLS9) as generally described in ref. [26] . Elution order of MDMA and HMMA glucuronide was determined by injection of a derivatized sample of the single S-stereoisomer [25, 28] . For determination of the elution order of HMA, additionally racemic MDA was incubated with HLS9.
Final Procedure for LC-MS/MS analysis
Blood plasma samples
Human blood samples (blank) were obtained from 10 different volunteers of the Zurich Institute of Forensic Medicine as lithium heparine blood. Blood plasma was obtained after centrifugation at 5,000g for 15 minutes and stored at -20 °C until further usage.
Sample Preparation and chiral derivatization of blood plasma
The plasma samples were prepared by simple protein precipitation. 
Apparatus
The analysis was performed using a Thermo Fischer Ultimate 3000 UHPLC system (Thermo The Turbo V ion source was operated in positive ESI mode with the following MS conditions: gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 4500; ion-source temperature, 550 °C; curtain gas, nitrogen (30 psi), collision gas, medium. The MS was operated in the multiple reaction monitoring (MRM) mode using 3 transitions for each analyte except for the ISs where 1 MRM transition was applied. The MS settings for each analyte are given in Table 1 .
Data analysis
Analyst software (1.6.2) was used for peak integration and quantification of data.
Method Validation
Preparation of calibration and quality control (QC) samples
Separate stock solutions (1 mM) of each racemic analyte and for the single diastereomers of HMMA 4-glucuronide were prepared in water/acetonitrile. Working solutions (1, 10, 50, 100, 200 mM) were prepared by dilution from each stock solution. Spiking solutions for calibration standards and QC samples were prepared by mixing appropriate amounts of the corresponding stock or working solution to obtain concentrations ten times higher than the corresponding blood plasma concentration. All solutions were stored in aliquots at -20°C.
Calibration standards and QC samples (LOW, MED, HIGH) were prepared from 200 µL analyte-free blood plasma and 20 µL of the corresponding fortifying solution. The final calibration and QC concentrations are given in Table 2 for each stereoisomer.
Selectivity and cross talk
50 µL of each analyte solution and each IS (100 µM) were derivatized separately as described above and analyzed for interferences in the other MRM transitions.
Specificity
Ten blank blood plasma samples from different sources were analyzed for peaks interfering with the detection of analytes or IS. Two zero samples (blank sample + IS) were analyzed to check for appropriate IS purity and presence of native analytes.
Recovery and matrix effects
Recovery (RE) and matrix effect (ME) were determined at QC LOW and HIGH concentration using 6 different blood plasma sources according to the simplified approach described by Matuszewski et al [37] .
Calibration model
Replicates (n=6) at each concentration level were analyzed as described above. The regression lines were calculated using non-weighted, a weighted 
Stability
Processed sample and freeze-thaw stability were investigated at QC LOW and HIGH concentration (n=6 each) according to ref. [38] . Long-term stability experiments for phase II metabolites were performed after 24 months at QC LOW and HIGH concentration (n = 6, each), calculated via a freshly prepared calibration curve and accuracy was compared to nominal concentrations.
Limits
The lowest point of the calibration curve was defined as the limit of quantification (LOQ) of the method and fulfilled the requirement of LOQ, signal to noise ratio of 10:1 determined via peak heights. The limit of detection (LOD) was not systematically investigated.
Proof of applicability
Blood plasma samples from a double-blind, placebo-controlled, crossover study with 125 mg of MDMA administered to healthy volunteers were assayed with the described method.
Results and discussion
LC-MS/MS Method Development
The S-enantiomer of MDMA is eliminated at a higher rate than the R-enantiomer The analytes included in the method were chosen based on the main metabolites identified in urine [20] and on the measurement of five authentic MDMA blood samples checking for all possible metabolites. In these samples mainly MDMA, HMMA 4-sulfate, HMMA 4-glucuronide, and DHMA 3-sulfate could be detected. Minor amounts of MDA, unconjugated HMMA, and DHMA 4-sulfate were present. DHMA and HMA as well as glucuronides of DHMA could not be detected in any of these samples. As DHMA and HMA were commercially available they were nevertheless included into the method.
As the final derivatives are not available as reference material derivatization had to be performed in order to produce these derivatives. Standard MS tuning procedures for MRM transitions did not work from this chemical reaction solvent, probably due to an excess of derivatization reagent still present in the mixture. Therefore determination of MRM transitions for the final method had to be performed manually. For that purpose, methods were written for each analyte targeting the underivatized, onefoldly derivatized and in cases where multiple derivatization was theoretically possible, two-and threefold derivatives. EPI spectra were recorded using a CE of 10 eV and 40 eV, respectively. No differences in the abundances of the fragment ions were observed between the R and S stereoisomers. As exemplarily depicted in Figure 3 for HMMA 4-sulfate-DNPV, from these EPI spectra three fragment ions and a reasonable CE were chosen per analyte for the final MRM method. For all analytes complete derivatization was observed. As derivatized DHMA sulfates were only detectable as deconjugated analytes after an in-source fragmentation and loss of the sulfate moiety, the deconjugated analytes were used as precusor ions for the final method.
The chosen derivatization procedure lead to the formation of diastereomers that should be separable on a chiral column. Using ammonium acetate (A) and ACN (B) as mobile phase, all analytes were nicely separated into their two stereoisomers, except for DHMA-DNPV. A change in mobile phase composition to ammonium formate and methanol allowed also the separation of DHMA-DNPV isomers, however, resulting in a coelution of MDA-DNPV and Furthermore derivatized analytes were analyzed for cross talk and interferences in the MRM transitions of the other analytes. Again, no cross talk for any compound could be detected.
This was one of the advantages of using derivatization in LC-MS. Usually, MDMA, MDA, HMMA, and HMA show very similar fragment ion and are prone to cross talk. Through oneand twofold derivatization, fragmentation was altered and resulted in different fragment ions.
Recovery and matrix effects
RE and ME data are listed in Table 3 . All analytes could be extracted with REs over 60% with acceptable CVs except for the glucuronides. Most probably, the used protein precipitation leads also to co-precipitation of part of the glucuronides. Different extraction procedures such as solid phase extraction or liquid liquid extraction were considered, however due to the large differences in the physico-chemical properties of MDMA and its phase II metabolites, discarded.
No notable MEs were observed for any of the analytes, except for HMMA 4-glucuronide-DNPV at QC LOW and for DHMA-DNPV. However, the ME for HMMA 4-glucuronide-DNPV was reproducible (CV < 11%) and was therefore accepted for pharmacokinetic studies.
The sensitivity for DHMA-DNPV was altogether rather low and its detection was only possible for QC MED and QC HIGH. Quite a large ME could be detected for DHMA-DNPV in QC HIGH (390%, CV 60%) by calculation via the area only. Adjustment via DHBA-DNPV as IS, which is generally used for quantification, lead to acceptable ME with 91% (19% CV) as given in Table 3 .
Calibration model
Calibration curves using six concentration levels with six replicates each were constructed to evaluate the calibration model. The limits for the calibration curve were assessed based on data published by [47] determined after controlled administration of MDMA. Calibration ranges for all analytes are given in Tables 2 and should 
Accuracy and precision
QC samples (LOW, MED, and HIGH) were analyzed in duplicate on each of eight days as was proposed by Peters et al [48] . QC concentrations were determined from daily calibration curves. Calibrator concentrations were within 30% of target based on the full calibration curve. Accuracy, intra-day and inter-day precision were calculated as described above (Table   3 ).
Respective deuterated analogues were employed for MDA and MDMA. As for all other metabolites no deuterated standards were commercially available, pholedrine was successfully used for HMMA 4-sulfate, HMMA 4-glucuronide, DHMA 3-sulfate, DHMA 4-sulfate, HMMA and HMA. DHMA was calculated with DHBA as IS due to its structural similarities.
All analytes fulfilled the validation parameters except for DHMA-DNPV, DHMA 4-sulfate-DNPV at QC LOW and HMMA-glucuronide-DNPV at QC LOW. As already mentioned the sensitivity for DHMA-DNPV was rather low, most likely due to the fact that it was threefoldly derivatized. It could be detected from concentrations equal or higher than calibrator 3 and QK MED. Even in QK MED and QK HIGH the inter-day precision was above the acceptance criteria of +/-15%. However, DHMA was not present in any of the analyzed authentic samples. For DHMA 4-sulfate-DNPV in QC LOW the observed bias was slightly lower than the acceptance criteria and for HMMA 4-glucuronide-DNPV intra-and interday precision was slightly above the acceptance criteria of +/-20%. No significant differences were observed between R-and S-stereoisomer. All together the method was sufficient for pharmacokinetic analysis of authentic samples after a controlled administration of MDMA in blood plasma.
Stability
No degradation was observed for any derivatized analyte in processed samples stored on the autosampler for 48 h at ambient temperature. All analytes were stable over three freeze-thaw cycles except for HMA, which was stable over only one cycle. Instability of HMA during freezing and thawing was already described by Kolbrich [49] . Therefore an immediate workup after thawing was recommended [49] which was performed for our samples.
No instability of the phase II analytes after storage at -20°C for 24 months was observed with calculated concentration within +/-20% of nominal concentration. Furthermore, no deconjugated analytes could be detected as would be assumed to be formed after degradation of phase II metabolites. Data on MDMA and its phase I metabolites as well as HMMA and HMA were previously published and no instability could be observed up to after 6 months [50] .
Limit of quantification
The LOQs of all analytes are listed in Table 2 and were consistent with the lowest calibrator with less than 30% bias as compared to the target concentration. Those limits were comparable to those published by other authors for MDMA and MDA [23, 49] and were sufficient for the pharmacokinetic analysis in the context of a controlled single MDMA administration study.
Proof of applicability
The presented method was successfully applied to about 500 samples of a pharmacokinetic study for MDMA following controlled MDMA administration. The data of this study will be presented elsewhere. As shown in Figure 5 , stereoselective differences could be seen in blood plasma samples after controlled MDMA administration. 
Conclusion
